DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Recruiting

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Elotuzumab in combination with pomalidomide and dexamethasone
Drug: Elotuzumab in combination with lenalidomide and dexamethasone

First Posted Date: 2023-12-08

Last Posted Date: 2024-09-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 27

Registration Number: NCT06163040

Locations: 🇨🇳
China Medical University Hospital, Taoyuan City, Taiwan
🇨🇳
Chang Gung Memorial Hospital- Chiayi, Chiayi City, Chiayi, Taiwan
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

and more 1 locations

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

Completed

Conditions: Melanoma

Interventions: Drug: Nivolumab +/- ipilimumab
Drug: Nivolumab

First Posted Date: 2023-12-08

Last Posted Date: 2024-04-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT06163170

Locations: 🇺🇸
Cardinal Health, Dublin, Ohio, United States

A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

Recruiting

Conditions: Cancer
Solid Tumors

Interventions: Drug: Immunotherapy

First Posted Date: 2023-12-08

Last Posted Date: 2023-12-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT06163053

Locations: 🇫🇷
CH Francois Quesnay, Mantes-La-Jolie, France
🇫🇷
CH de Pau, Pau, France
🇫🇷
CH Metropole Savoie, Chambéry, France

Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

Completed

Conditions: Multiple Myeloma

Interventions: Drug: No IMiD treatment
Drug: IMiD treatment
Drug: Systemic therapy

First Posted Date: 2023-12-07

Last Posted Date: 2024-08-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4204

Registration Number: NCT06160167

Locations: 🇺🇸
Flatiron Health Oncology Database, New York, New York, United States

Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Other: Not treated
Drug: Idecabtagene vicleucel

First Posted Date: 2023-12-04

Last Posted Date: 2023-12-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 350

Registration Number: NCT06154902

Locations: 🇫🇷
DESCAR-T Registry, Paris, France

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Mavacamten

First Posted Date: 2023-11-27

Last Posted Date: 2024-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 600

Registration Number: NCT06146660

Locations: 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷
Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy Participants

Interventions: Drug: BMS-986465
Other: Placebo
Drug: Famotidine
Drug: Pegasys

First Posted Date: 2023-11-22

Last Posted Date: 2025-02-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 267

Registration Number: NCT06144697

Locations: 🇺🇸
Local Institution - 0003, Austin, Texas, United States
🇺🇸
Local Institution - 0001, Anaheim, California, United States

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Phase 3

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Crizotinib
Drug: Repotrectinib

First Posted Date: 2023-11-20

Last Posted Date: 2025-05-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 190

Registration Number: NCT06140836

Locations: 🇺🇸
Local Institution - 0136, Augusta, Georgia, United States
🇺🇸
Local Institution - 0221, Des Moines, Iowa, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 141 locations

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ozanimod
Drug: Select DMTs other than ozanimod
Drug: No DMTs

First Posted Date: 2023-11-15

Last Posted Date: 2023-11-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2961

Registration Number: NCT06133049

Locations: 🇺🇸
OptumInsight Life Sciences Inc, Eden Prairie, Minnesota, United States

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants

Active, not recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Ozanimod
Drug: Conventional therapy
Drug: Advanced therapy

First Posted Date: 2023-11-13

Last Posted Date: 2024-10-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2828

Registration Number: NCT06126835

Locations: 🇺🇸
OptumInsight Life Sciences Inc, Eden Prairie, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy